{
    "doi": "https://doi.org/10.1182/blood.V116.21.3509.3509",
    "article_title": "Significant Improvement In Day 100 and 1-Year Overall Survival In Patients Who Underwent Myeloablative Allogeneic Hematopoietic Cell Transplant In the US or Canada Between 1994 and 2005 ",
    "article_date": "November 19, 2010",
    "session_type": "Clinical Results - Allogeneic Matched Related Donor Transplantation: Poster I",
    "abstract_text": "Abstract 3509 Allogeneic hematopoietic cell transplantation (alloHCT) has become standard therapy for hematologic disorders and malignancies. We assessed whether overall survival (OS) at 100 days, which represents early transplant-related mortality (TRM), and at one year, which represents disease-related mortality and later TRM, had changed over time. The study population was derived from patients undergoing 38,060 first alloHCTs between 1994\u20132005 in US and Canadian centers and reported to the CIBMTR. Donor lymphocyte infusions were excluded. Statistical significance was measured using P trend over 6 time cohorts to test whether the OS estimates were stable (slope = 0), increasing (slope>0) or decreasing (slope<0) over time. The Day 100 and 1 year OS estimates are shown in the Table . Disease and disease status subgroups were defined a priori , and the OS estimates are not adjusted for any covariates such as age, Karnofsky status, etc. Marked improvements in 100-day survival were seen for all disease and disease status groups examined. Day 100 mortality rates in HLA-matched sibling alloHCT recipients during the most recent period (2004-5) were as low as 2% for CML treated in CP1, 6\u20138% for AML in CR1 and ALL in CR2, and a modest 12% for MDS. Even in alloHCT recipients with unrelated donors treated in 2004-5, the Day 100 mortality rates ranged from 9\u201322%, a significant decrease from historical mortality rates of 29\u201337%. Significant improvements in 1-year OS were noted for all groups undergoing unrelated-donor alloHCT; however, among those undergoing HLA-matched sibling alloHCT, significant improvements in 1-year OS were only seen in patients with CML in CP1 or MDS. OS has improved for many patients undergoing myeloablative alloHCT, which likely reflects improvement in supportive care and better patient/donor selection. Day 100 OS has significantly improved in all patients who received a myeloablative HLA-matched related or unrelated donor alloHCT. Significant improvement in 1-year OS was also experienced by most patients. Table: Overall survival (95% CI) estimates over time  HLA-Matched Sibling Myeloablative Allogeneic HCT . . 1994-5 . 1996-7 . 1998-9 . 2000-1 . 2002-3 . 2004-5 . P trend . AML in CR1   N  370  370  383  376  384  440  <0.001   @100 days  85 (81\u201388)  87 (84\u201390)  90 (86\u201393)  88 (84\u201391)  92 (89\u201394)  94 (91\u201396)  0.1662   @1 year  69 (65\u201374)  70 (66\u201375)  72 (67\u201376)  67 (62\u201372)  74 (69\u201378)  75 (71\u201380)   ALL in CR2+   N  179  186  149  159  156  163  0.0018   @100 days  77 (70\u201383)  82 (76\u201387)  88 (82\u201393)  85 (79\u201390)  85 (79\u201390)  92 (87\u201396)  0.2937   @1 year  62 (55\u201369)  63 (56\u201370)  69 (61\u201377)  59 (51\u201367)  64 (56\u201371)  70 (62\u201377)   CML in CP1   N  483  540  492  317  155  125  <0.001   @100 days  84 (81\u201387)  88 (85\u201390)  89 (87\u201392)  91 (87\u201394)  99 (96\u2013100)  98 (94\u2013100)  <0.001   @1 year  71 (66\u201375)  72 (68\u201376)  80 (76\u201383)  82 (77\u201386)  89 (83\u201393)  92 (86\u201396)   MDS   N  225  290  273  235  239  227  <0.001   @100 days  71 (65\u201377) 75 (70\u201380) 76 (71\u201381) 82 (77\u201387) 85 (80\u201389) 88 (84\u201392) 0.0488   @1 year  54 (48\u201361)  51 (45\u201357)  57 (51\u201363)  58 (51\u201365)  61 (55\u201368)  64 (58\u201371)   HLA-Matched Sibling Myeloablative Allogeneic HCT . . 1994-5 . 1996-7 . 1998-9 . 2000-1 . 2002-3 . 2004-5 . P trend . AML in CR1   N  370  370  383  376  384  440  <0.001   @100 days  85 (81\u201388)  87 (84\u201390)  90 (86\u201393)  88 (84\u201391)  92 (89\u201394)  94 (91\u201396)  0.1662   @1 year  69 (65\u201374)  70 (66\u201375)  72 (67\u201376)  67 (62\u201372)  74 (69\u201378)  75 (71\u201380)   ALL in CR2+   N  179  186  149  159  156  163  0.0018   @100 days  77 (70\u201383)  82 (76\u201387)  88 (82\u201393)  85 (79\u201390)  85 (79\u201390)  92 (87\u201396)  0.2937   @1 year  62 (55\u201369)  63 (56\u201370)  69 (61\u201377)  59 (51\u201367)  64 (56\u201371)  70 (62\u201377)   CML in CP1   N  483  540  492  317  155  125  <0.001   @100 days  84 (81\u201387)  88 (85\u201390)  89 (87\u201392)  91 (87\u201394)  99 (96\u2013100)  98 (94\u2013100)  <0.001   @1 year  71 (66\u201375)  72 (68\u201376)  80 (76\u201383)  82 (77\u201386)  89 (83\u201393)  92 (86\u201396)   MDS   N  225  290  273  235  239  227  <0.001   @100 days  71 (65\u201377) 75 (70\u201380) 76 (71\u201381) 82 (77\u201387) 85 (80\u201389) 88 (84\u201392) 0.0488   @1 year  54 (48\u201361)  51 (45\u201357)  57 (51\u201363)  58 (51\u201365)  61 (55\u201368)  64 (58\u201371)   View Large  Unrelated Donor Myeloablative Allogeneic HCT . . 1994-5 . 1996-7 . 1998-9 . 2000-1 . 2002-3 . 2004-5 . P trend . AML in CR1   N  52  75  88  135  182  336  <0.001 @100 days 63 (50\u201376) 64 (53\u201374) 69 (59\u201378) 75 (68\u201382) 82 (76\u201387) 86 (82\u201390) 0.0427   @1 year  48 (35\u201362)  35 (25\u201347)  48 (37\u201359)  51 (42\u201360)  54 (46\u201361)  56 (50\u201362)   ALL in CR2+   N  129  151  132  116  164  197  <0.001   @100 days  66 (58\u201374) 70 (62\u201377) 71 (62\u201378) 75 (67\u201382) 78 (71\u201384) 91 (87\u201395) <0.001   @1 year  43 (34\u201351)  45 (37\u201353)  49 (40\u201358)  40 (31\u201350)  54 (46\u201362)  67 (60\u201374)   CML in CP1   N  211  250  292  152  87  118  0.0006   @100 days  71 (65\u201377) 70 (64\u201375) 74 (69\u201379) 75 (68\u201381) 80 (71\u201388) 87 (81\u201393) 0.0057   @1 year  51 (44\u201357)  54 (48\u201361)  59 (53\u201364)  60 (52\u201368)  65 (54\u201375)  71 (62\u201380)   MDS   N  104  138  135  140  161  234  <0.001   @100 days  64 (54\u201373) 62 (54\u201370) 59 (51\u201367) 67 (59\u201375) 74 (67\u201381) 78 (72\u201383) <0.001   @1 year  41 (31\u201350)  44 (35\u201352)  35 (27\u201343)  45 (37\u201354)  52 (44\u201360)  57 (50\u201363)   Unrelated Donor Myeloablative Allogeneic HCT . . 1994-5 . 1996-7 . 1998-9 . 2000-1 . 2002-3 . 2004-5 . P trend . AML in CR1   N  52  75  88  135  182  336  <0.001 @100 days 63 (50\u201376) 64 (53\u201374) 69 (59\u201378) 75 (68\u201382) 82 (76\u201387) 86 (82\u201390) 0.0427   @1 year  48 (35\u201362)  35 (25\u201347)  48 (37\u201359)  51 (42\u201360)  54 (46\u201361)  56 (50\u201362)   ALL in CR2+   N  129  151  132  116  164  197  <0.001   @100 days  66 (58\u201374) 70 (62\u201377) 71 (62\u201378) 75 (67\u201382) 78 (71\u201384) 91 (87\u201395) <0.001   @1 year  43 (34\u201351)  45 (37\u201353)  49 (40\u201358)  40 (31\u201350)  54 (46\u201362)  67 (60\u201374)   CML in CP1   N  211  250  292  152  87  118  0.0006   @100 days  71 (65\u201377) 70 (64\u201375) 74 (69\u201379) 75 (68\u201381) 80 (71\u201388) 87 (81\u201393) 0.0057   @1 year  51 (44\u201357)  54 (48\u201361)  59 (53\u201364)  60 (52\u201368)  65 (54\u201375)  71 (62\u201380)   MDS   N  104  138  135  140  161  234  <0.001   @100 days  64 (54\u201373) 62 (54\u201370) 59 (51\u201367) 67 (59\u201375) 74 (67\u201381) 78 (72\u201383) <0.001   @1 year  41 (31\u201350)  44 (35\u201352)  35 (27\u201343)  45 (37\u201354)  52 (44\u201360)  57 (50\u201363)   View Large Disclosures: No relevant conflicts of interest to declare.",
    "topics": [
        "allogeneic hematopoietic stem cell transplant",
        "human leukocyte antigens",
        "cancer",
        "hematological diseases",
        "hematopoietic stem cell transplantation",
        "supportive care",
        "transplantation",
        "donors",
        "lymphocytes"
    ],
    "author_names": [
        "Theresa Hahn, PhD",
        "Philip L. McCarthy, MD",
        "Anna Hassebroek, MPH",
        "John P. Klein, PhD",
        "J. Douglas Rizzo, MD, MS",
        "Susan Parsons, MD, MRP",
        "Steven Joffe, MD, MPH",
        "Navneet S. Majhail, MD, MS"
    ],
    "author_dict_list": [
        {
            "author_name": "Theresa Hahn, PhD",
            "author_affiliations": [
                "Dept. of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Philip L. McCarthy, MD",
            "author_affiliations": [
                "BMT Program, Roswell Park Cancer Institute, Buffalo, NY, USA, "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Anna Hassebroek, MPH",
            "author_affiliations": [
                "Center for International Blood and Marrow Transplant Research, Minneapolis, MN, "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "John P. Klein, PhD",
            "author_affiliations": [
                "Department of Biostatistics, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "J. Douglas Rizzo, MD, MS",
            "author_affiliations": [
                "Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Susan Parsons, MD, MRP",
            "author_affiliations": [
                "The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Steven Joffe, MD, MPH",
            "author_affiliations": [
                "Dana-Farber Cancer Institute, Boston, MA, "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Navneet S. Majhail, MD, MS",
            "author_affiliations": [
                "Hematology and Oncology (IM) Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA"
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-16T15:42:19",
    "is_scraped": "1"
}